JAK2 and Alzheimer disease: Topical application of Momelotinib, a novel Janus kinase (JAK)1/JAK2 inhibitor, suppressed STAT3 signaling, the release of pro-inflammatory cytokines, total serum IgE levels, and mast cell infiltration, and thus improved the symptoms of AD (15).